<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39234238</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>05</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Post-marketing drug safety surveillance of enfortumab vedotin: an observational pharmacovigilance study based on a real-world database.</ArticleTitle><Pagination><StartPage>1397692</StartPage><MedlinePgn>1397692</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1397692</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2024.1397692</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Enfortumab vedotin (EV) is an antibody-drug conjugate (ADC) that has been approved by the FDA for patients with locally advanced or metastatic urothelial carcinoma (UC). This study presents a comprehensive pharmacovigilance analysis of the post-marketing safety profile of EV in the real-world based on the US Food and Drug Administration Adverse Event Reporting System (FAERS).</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Adverse event (AE) reports regarding EV between January 2020 and December 2023 were obtained from the FAERS database. The standardized MedDRA query (SMQ) narrow search AEs on the preferred term (PT) level were used. Disproportionality analysis was performed to identify the AE signals for EV with the reporting odds ratio (ROR), proportional reporting ratio (PRR), multi-item gamma Poisson shrinker (MGPS), and Bayesian confidence propagation neural network (BCPNN).</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 2,216 reports regarding EV were included in the present study. SMQ analysis results indicated that a stronger strength signal was found in severe cutaneous adverse reactions, retroperitoneal fibrosis, and peripheral neuropathy. A total of 116 significant disproportionality PTs referring to 14 system organ classes (SOCs) were retained by disproportionality analysis, with 49 PTs not listed on the EV drug label. Frequently reported EV-related AEs included rash, peripheral neuropathy, decreased appetite, alopecia, and pruritus. The time to onset of the majority of EV-related AEs was within 30 days (66.05%), with only 0.73% events occurring after 1 year.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">The disproportionality analysis highlights that dermatologic toxicity and peripheral neuropathy were the major AEs induced by EV. The potential AEs not listed on the drug label were mainly related to gastrointestinal, hepatic, and pulmonary events. Further research is needed to confirm and explore the EV-related AEs in clinical practice.</AbstractText><CopyrightInformation>Copyright © 2024 Yu, Zhou, Cao, Ji and Zheng.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Yu</LastName><ForeName>Mingming</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Ultrasound in Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhou</LastName><ForeName>Lijun</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Urology, Shanghai Children's Hospital, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Mengda</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ji</LastName><ForeName>Chunmei</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Yuanyi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Ultrasound in Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018796">Immunoconjugates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060735" MajorTopicYN="Y">Pharmacovigilance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011358" MajorTopicYN="Y">Product Surveillance, Postmarketing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016907" MajorTopicYN="Y">Adverse Drug Reaction Reporting Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="Y">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018796" MajorTopicYN="N">Immunoconjugates</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014486" MajorTopicYN="N">United States Food and Drug Administration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FDA Adverse Event Reporting System</Keyword><Keyword MajorTopicYN="N">adverse event</Keyword><Keyword MajorTopicYN="N">disproportionality analysis</Keyword><Keyword MajorTopicYN="N">enfortumab vedotin</Keyword><Keyword MajorTopicYN="N">real-world</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>5</Day><Hour>4</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39234238</ArticleId><ArticleId IdType="pmc">PMC11372787</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2024.1397692</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2021) 71:209–49. doi: 10.3322/caac.21660</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21660</ArticleId><ArticleId IdType="pubmed">33538338</ArticleId></ArticleIdList></Reference><Reference><Citation>Halford Z, Anderson MK, Clark MD. Enfortumab vedotin-ejfv: A first-in-class anti-nectin-4 antibody-drug conjugate for the management of urothelial carcinoma. Ann Pharmacother. (2021) 55:772–82. doi: 10.1177/1060028020960402</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1060028020960402</ArticleId><ArticleId IdType="pubmed">32945172</ArticleId></ArticleIdList></Reference><Reference><Citation>Cathomas R, Lorch A, Bruins HM, Compérat EM, Cowan NC, Efstathiou JA, et al. . The 2021 updated european association of urology guidelines on metastatic urothelial carcinoma. Eur Urol. (2022) 81:95–103. doi: 10.1016/j.eururo.2021.09.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2021.09.026</ArticleId><ArticleId IdType="pubmed">34742583</ArticleId></ArticleIdList></Reference><Reference><Citation>Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, et al. . NCCN guidelines® Insights: bladder cancer, version 2.2022. J Natl Compr Canc Netw. (2022) 20:866–78. doi: 10.6004/jnccn.2022.0041</Citation><ArticleIdList><ArticleId IdType="doi">10.6004/jnccn.2022.0041</ArticleId><ArticleId IdType="pubmed">35948037</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh AM, Guevara-Patino JA, Wang X, Li R, Sonpavde G, Jain RK. Antibody-drug conjugates in the treatment of urothelial cancer. BioDrugs. (2023) 37:505–20. doi: 10.1007/s40259-023-00606-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40259-023-00606-5</ArticleId><ArticleId IdType="pubmed">37256534</ArticleId></ArticleIdList></Reference><Reference><Citation>Challita-Eid PM, Satpayev D, Yang P, An Z, Morrison K, Shostak Y, et al. . Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res. (2016) 76:3003–13. doi: 10.1158/0008-5472.Can-15-1313</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.Can-15-1313</ArticleId><ArticleId IdType="pubmed">27013195</ArticleId></ArticleIdList></Reference><Reference><Citation>Padua TC, Moschini M, Martini A, Pederzoli F, Nocera L, Marandino L, et al. . Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review. Urol Oncol. (2022) 40:413–23. doi: 10.1016/j.urolonc.2022.07.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urolonc.2022.07.006</ArticleId><ArticleId IdType="pubmed">35973928</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouleftour W, Sargos P, Magne N. Nectin-4: a tumor cell target and status of inhibitor development. Curr Oncol Rep. (2023) 25:181–8. doi: 10.1007/s11912-023-01360-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11912-023-01360-1</ArticleId><ArticleId IdType="pubmed">36696077</ArticleId></ArticleIdList></Reference><Reference><Citation>Shafique MA, Haseeb A, Siddiq MA, Mussarat A, Rangwala HS, Mustafa MS. Current and emerging treatments for urothelial carcinoma: A focus on enfortumab vedotin. Cancer Manag Res. (2023) 15:699–706. doi: 10.2147/cmar.S418009</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/cmar.S418009</ArticleId><ArticleId IdType="pmc">PMC10362867</ArticleId><ArticleId IdType="pubmed">37485038</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg JE, O’Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, et al. . Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. J Clin Oncol. (2019) 37:2592–600. doi: 10.1200/jco.19.01140</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.19.01140</ArticleId><ArticleId IdType="pmc">PMC6784850</ArticleId><ArticleId IdType="pubmed">31356140</ArticleId></ArticleIdList></Reference><Reference><Citation>McGregor B, O’Donnell PH, Balar A, Petrylak D, Rosenberg J, Yu EY, et al. . Health-related quality of life of patients with locally advanced or metastatic urothelial cancer treated with enfortumab vedotin after platinum and PD-1/PD-L1 inhibitor therapy: results from cohort 1 of the phase 2 EV-201 clinical trial. Eur Urol. (2022) 81:515–22. doi: 10.1016/j.eururo.2022.01.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2022.01.032</ArticleId><ArticleId IdType="pmc">PMC9385268</ArticleId><ArticleId IdType="pubmed">35168844</ArticleId></ArticleIdList></Reference><Reference><Citation>Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Durán I, Lee JL, et al. . Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. (2021) 384:1125–35. doi: 10.1056/NEJMoa2035807</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035807</ArticleId><ArticleId IdType="pmc">PMC8450892</ArticleId><ArticleId IdType="pubmed">33577729</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu EY, Petrylak DP, O’Donnell PH, Lee JL, van der Heijden MS, Loriot Y, et al. . Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV−201): a multicentre, single-arm, phase 2 trial. Lancet Oncol. (2021) 22:872–82. doi: 10.1016/s1470-2045(21)00094-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1470-2045(21)00094-2</ArticleId><ArticleId IdType="pubmed">33991512</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsubara N, Yonese J, Kojima T, Azuma H, Matsumoto H, Powles T, et al. . Japanese subgroup analysis of EV-301: An open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma. Cancer Med. (2023) 12:2761–71. doi: 10.1002/cam4.5165</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.5165</ArticleId><ArticleId IdType="pmc">PMC9939146</ArticleId><ArticleId IdType="pubmed">36052536</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhindi B, Kool R, Kulkarni GS, Siemens DR, Aprikian AG, Breau RH, et al. . Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Full-text. Can Urol Assoc J. (2021) 15:E424–e460. doi: 10.5489/cuaj.7367</Citation><ArticleIdList><ArticleId IdType="doi">10.5489/cuaj.7367</ArticleId><ArticleId IdType="pmc">PMC8418246</ArticleId><ArticleId IdType="pubmed">33938798</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistic. CA Cancer J Clin. (2023) 73:17–48. doi: 10.3322/caac.21763</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21763</ArticleId><ArticleId IdType="pubmed">36633525</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanna KS. Clinical overview of enfortumab vedotin in the management of locally advanced or metastatic urothelial carcinoma. Drugs. (2020) 80:1–7. doi: 10.1007/s40265-019-01241-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-019-01241-7</ArticleId><ArticleId IdType="pubmed">31823332</ArticleId></ArticleIdList></Reference><Reference><Citation>van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. (2002) 11:3–10. doi: 10.1002/pds.668</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.668</ArticleId><ArticleId IdType="pubmed">11998548</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauben M, Madigan D, Gerrits CM, Walsh L, Van Puijenbroek EP. The role of data mining in pharmacovigilance. Expert Opin Drug Saf. (2005) 4:929–48. doi: 10.1517/14740338.4.5.929</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14740338.4.5.929</ArticleId><ArticleId IdType="pubmed">16111454</ArticleId></ArticleIdList></Reference><Reference><Citation>Lao DH, Chen Y, Fan J, Zhang JZ. Assessing taxane-associated adverse events using the FDA adverse event reporting system database. Chin Med J (Engl). (2021) 134:1471–6. doi: 10.1097/cm9.0000000000001562</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/cm9.0000000000001562</ArticleId><ArticleId IdType="pmc">PMC8213312</ArticleId><ArticleId IdType="pubmed">34074841</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg J, Sridhar SS, Zhang J, Smith D, Ruether D, Flaig TW, et al. . EV-101: A phase I study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma. J Clin Oncol. (2020) 38:1041–9. doi: 10.1200/jco.19.02044</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.19.02044</ArticleId><ArticleId IdType="pmc">PMC7106979</ArticleId><ArticleId IdType="pubmed">32031899</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Donnell PH, Milowsky MI, Petrylak DP, Hoimes CJ, Flaig TW, Mar N, et al. . Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer. J Clin Oncol. (2023) 41:4107–17. doi: 10.1200/jco.22.02887</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.22.02887</ArticleId><ArticleId IdType="pmc">PMC10852367</ArticleId><ArticleId IdType="pubmed">37369081</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg JE, Powles T, Sonpavde GP, Loriot Y, Duran I, Lee JL, et al. . EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma. Ann Oncol. (2023) 34:1047–54. doi: 10.1016/j.annonc.2023.08.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annonc.2023.08.016</ArticleId><ArticleId IdType="pubmed">37678672</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirotsu KE, Rana J, Wang JY, Raghavan SS, Rieger KE, Srinivas S, et al. . Clinicopathologic characterization of enfortumab vedotin-associated cutaneous toxicity in patients with urothelial carcinoma. J Am Acad Dermatol. (2021) 85:1610–1. doi: 10.1016/j.jaad.2020.11.067</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2020.11.067</ArticleId><ArticleId IdType="pubmed">33301805</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacouture ME, Patel AB, Rosenberg JE, O’Donnell PH. Management of dermatologic events associated with the nectin-4-directed antibody-drug conjugate enfortumab vedotin. Oncologist. (2022) 27:e223–32. doi: 10.1093/oncolo/oyac001</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oncolo/oyac001</ArticleId><ArticleId IdType="pmc">PMC8914492</ArticleId><ArticleId IdType="pubmed">35274723</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong RL, Yu EY. Enfortumab vedotin in the treatment of urothelial cancers and beyond. Future Oncol. (2022) 18:3067–84. doi: 10.2217/fon-2022-0328</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fon-2022-0328</ArticleId><ArticleId IdType="pubmed">36004667</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen MN, Reyes M, Jones SC. Postmarketing cases of enfortumab vedotin-associated skin reactions reported as stevens-johnson syndrome or toxic epidermal necrolysis. JAMA Dermatol. (2021) 157:1237–9. doi: 10.1001/jamadermatol.2021.3450</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamadermatol.2021.3450</ArticleId><ArticleId IdType="pmc">PMC8427493</ArticleId><ArticleId IdType="pubmed">34495281</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H, Yu X, An Z. Cutaneous toxicity associated with enfortumab vedotin: A real-word study leveraging U.S. Food and drug administration adverse event reporting system. Front Oncol. (2021) 11:801199. doi: 10.3389/fonc.2021.801199</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2021.801199</ArticleId><ArticleId IdType="pmc">PMC8807512</ArticleId><ArticleId IdType="pubmed">35127510</ArticleId></ArticleIdList></Reference><Reference><Citation>Pace A, Brower B, Conway D, Leis D. Enfortumab vedotin: nursing perspectives on the management of adverse events in patients with locally advanced or metastatic urothelial carcinoma. Clin J Oncol Nurs. (2021) 25:E1–e9. doi: 10.1188/21.Cjon.E1-e9</Citation><ArticleIdList><ArticleId IdType="doi">10.1188/21.Cjon.E1-e9</ArticleId><ArticleId IdType="pubmed">33739346</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Liu L, Fan S, Xiao D, Xie F, Li W, et al. . Antibody-drug conjugate using ionized cys-linker-MMAE as the potent payload shows optimal therapeutic safety. Cancers (Basel). (2020) 12:744. doi: 10.3390/cancers12030744</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers12030744</ArticleId><ArticleId IdType="pmc">PMC7140114</ArticleId><ArticleId IdType="pubmed">32245171</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakisaka T, Ikeda W, Ogita H, Fujita N, Takai Y. The roles of nectins in cell adhesions: cooperation with other cell adhesion molecules and growth factor receptors. Curr Opin Cell Biol. (2007) 19:593–602. doi: 10.1016/j.ceb.2007.09.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ceb.2007.09.007</ArticleId><ArticleId IdType="pubmed">17942295</ArticleId></ArticleIdList></Reference><Reference><Citation>Takai Y, Miyoshi J, Ikeda W, Ogita H. Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation. Nat Rev Mol Cell Biol. (2008) 9:603–15. doi: 10.1038/nrm2457</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm2457</ArticleId><ArticleId IdType="pubmed">18648374</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y, Liu K, Wang K, Zhu H. Treatment-related adverse events of antibody-drug conjugates in clinical trials: A systematic review and meta-analysis. Cancer. (2023) 129:283–95. doi: 10.1002/cncr.34507</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.34507</ArticleId><ArticleId IdType="pmc">PMC10099922</ArticleId><ArticleId IdType="pubmed">36408673</ArticleId></ArticleIdList></Reference><Reference><Citation>Best RL, LaPointe NE, Azarenko O, Miller H, Genualdi C, Chih S, et al. . Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): Mechanistic insights into MMAE ADC peripheral neuropathy. Toxicol Appl Pharmacol. (2021) 421:115534. doi: 10.1016/j.taap.2021.115534</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.taap.2021.115534</ArticleId><ArticleId IdType="pubmed">33852878</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters JC, Nickens DJ, Xuan D, Shazer RL, Amantea M. Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads. Invest New Drugs. (2018) 36:121–35. doi: 10.1007/s10637-017-0520-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10637-017-0520-6</ArticleId><ArticleId IdType="pubmed">29027591</ArticleId></ArticleIdList></Reference><Reference><Citation>Donaghy H. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs. (2016) 8:659–71. doi: 10.1080/19420862.2016.1156829</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19420862.2016.1156829</ArticleId><ArticleId IdType="pmc">PMC4966843</ArticleId><ArticleId IdType="pubmed">27045800</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Z, Liu T, Wei J, Wang A, He Y, Yang L, et al. . Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study. Cancer Commun (Lond). (2021) 41:1173–82. doi: 10.1002/cac2.12214</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cac2.12214</ArticleId><ArticleId IdType="pmc">PMC8626607</ArticleId><ArticleId IdType="pubmed">34665942</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng X, Yan X, Wang L, Shi Y, Yao X, Luo H, et al. . Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma. Clin Cancer Res. (2021) 27:43–51. doi: 10.1158/1078-0432.Ccr-20-2488</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.Ccr-20-2488</ArticleId><ArticleId IdType="pubmed">33109737</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun C, Yang X, Tang L, Chen J. A pharmacovigilance study on drug-induced liver injury associated with antibody-drug conjugates (ADCs) based on the food and drug administration adverse event reporting system. Expert Opin Drug Saf. (2024) 23:1049–60. doi: 10.1080/14740338.2023.2277801</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14740338.2023.2277801</ArticleId><ArticleId IdType="pubmed">37898875</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin W, Xu J, Liao Y, Lin X, Yang J, Zhuang W. Assessing safety concerns of interstitial lung disease associated with antibody-drug conjugates: a real-world pharmacovigilance evaluation of the FDA adverse event reporting system. Int J Clin Pharm. (2024) 46:614–22. doi: 10.1007/s11096-023-01673-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11096-023-01673-y</ArticleId><ArticleId IdType="pubmed">38100054</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>